Immune Thrombocytopenic Purpura Complicated by Hepatitis C Virus-related Membranoproliferative Glomerulonephritis after Rituximab Therapy
| Autor: | Ai Kubodera, Hiroaki Tanaka, Yoshihiro Miyauchi, Yoshio Suzuki, Akihiro Miyakawa, Kiyohito Hayashi, Ryo Shimizu, Ayaka Kume |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
hepatitis C virus
Male Exacerbation Glomerulonephritis Membranoproliferative membranoproliferative glomerulonephritis Hepatitis C virus Case Report Hepacivirus medicine.disease_cause rituximab Immune system immune system diseases Rituximab therapy hemic and lymphatic diseases Membranoproliferative glomerulonephritis Internal Medicine medicine Humans Purpura Thrombocytopenic Idiopathic business.industry Antiviral therapy virus diseases General Medicine Middle Aged medicine.disease Hepatitis C Thrombocytopenic purpura digestive system diseases immune thrombocytopenia Immunology Rituximab business medicine.drug |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| DOI: | 10.2169/internalmedicine.6758-20 |
| Popis: | We herein report the case of a 54-year-old Japanese man with hepatitis C virus (HCV)-related membranoproliferative glomerulonephritis (MPGN), which developed at the time of relapse of immune thrombocytopenic purpura (ITP) after rituximab therapy. Antiviral therapy for HCV led to the improvement of both MPGN and ITP. Rituximab therapy may have contributed to the exacerbation of HCV infection and induced the development of HCV-related MPGN and the relapse of ITP. Our case suggested that HCV treatment should be prioritized over rituximab therapy for HCV-positive patients with ITP and that antiviral therapy for HCV may be effective for treating ITP itself. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|